{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Receptors%2C+Fibroblast+Growth+Factor&page=2", "query": { "condition": "Receptors, Fibroblast Growth Factor", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Receptors%2C+Fibroblast+Growth+Factor&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-23T09:19:57.931Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04595747", "title": "Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced Gastrointestinal Stromal Tumor", "Locally Advanced Sarcoma", "Metastatic Gastrointestinal Stromal Tumor", "Metastatic Sarcoma", "Stage III Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8", "Stage III Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8", "Stage IV Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8", "Stage IV Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Rogaratinib", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2021-05-03", "completion_date": "2027-07-31", "has_results": false, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-07-23T09:19:57.931Z", "location_count": 18, "location_summary": "Duarte, California • Irvine, California • Aurora, Colorado + 13 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Plantation", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04595747" }, { "nct_id": "NCT06164951", "title": "A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Achondroplasia" ], "interventions": [ { "name": "Infigratinib 0.25 mg/kg/day", "type": "DRUG" }, { "name": "Placebo Comparator 0.25 mg/kg/day", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "QED Therapeutics, a BridgeBio company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "3 Years to 17 Years" }, "enrollment_count": 114, "start_date": "2023-11-10", "completion_date": "2025-12-18", "has_results": false, "last_update_posted_date": "2026-03-17", "last_synced_at": "2026-07-23T09:19:57.931Z", "location_count": 7, "location_summary": "San Francisco, California • Aurora, Colorado • Baltimore, Maryland + 4 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Columbia", "state": "Missouri" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06164951" }, { "nct_id": "NCT05145010", "title": "Extension Study of Infigratinib in Children With Achondroplasia (ACH)", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Achondroplasia" ], "interventions": [ { "name": "Infigratinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "QED Therapeutics, a BridgeBio company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "3 Years to 18 Years" }, "enrollment_count": 300, "start_date": "2021-12-06", "completion_date": "2032-02-01", "has_results": false, "last_update_posted_date": "2025-10-31", "last_synced_at": "2026-07-23T09:19:57.931Z", "location_count": 8, "location_summary": "Oakland, California • Aurora, Colorado • Wilmington, Delaware + 5 more", "locations": [ { "city": "Oakland", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Wilmington", "state": "Delaware" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Columbia", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT05145010" }, { "nct_id": "NCT06625593", "title": "A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "BG-C137", "type": "DRUG" }, { "name": "Anticancer Agents", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeOne Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 168, "start_date": "2024-12-09", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-07-09", "last_synced_at": "2026-07-23T09:19:57.931Z", "location_count": 6, "location_summary": "Los Angeles, California • New Haven, Connecticut • Rochester, Minnesota + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Houston", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT06625593" }, { "nct_id": "NCT04024436", "title": "A Study of TAS-120 in Patients With Metastatic Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer", "FGFR 1 High Amplification", "FGFR2 Amplification" ], "interventions": [ { "name": "Futibatinib", "type": "DRUG" }, { "name": "Futibatinib plus Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Taiho Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2020-01-28", "completion_date": "2023-09-06", "has_results": true, "last_update_posted_date": "2025-11-13", "last_synced_at": "2026-07-23T09:19:57.931Z", "location_count": 17, "location_summary": "Phoenix, Arizona • San Francisco, California • Fort Myers, Florida + 12 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04024436" }, { "nct_id": "NCT04003610", "title": "Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Urothelial Carcinoma", "Unresectable Urothelial Carcinoma" ], "interventions": [ { "name": "Pemigatinib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2020-05-14", "completion_date": "2021-04-18", "has_results": true, "last_update_posted_date": "2025-11-04", "last_synced_at": "2026-07-23T09:19:57.931Z", "location_count": 13, "location_summary": "Greenbrae, California • Newark, Delaware • Marietta, Georgia + 10 more", "locations": [ { "city": "Greenbrae", "state": "California" }, { "city": "Newark", "state": "Delaware" }, { "city": "Marietta", "state": "Georgia" }, { "city": "Springfield", "state": "Illinois" }, { "city": "Westwood", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04003610" }, { "nct_id": "NCT02038673", "title": "An Open-label Phase I Study of Orally Available Novel Small-molecule Fibroblast Growth Factor Receptors (FGFR) 1,2,3 and 4 Inhibitor, ASP5878 at Single and Multiple Doses in Patients With Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "ASP5878", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "20 Years", "maximum_age": null, "sex": "ALL", "summary": "20 Years and older" }, "enrollment_count": 86, "start_date": "2013-11-05", "completion_date": "2017-07-19", "has_results": false, "last_update_posted_date": "2024-10-31", "last_synced_at": "2026-07-23T09:19:57.931Z", "location_count": 6, "location_summary": "Orange, California • New York, New York • Cleveland, Ohio + 3 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Spartanburg", "state": "South Carolina" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02038673" }, { "nct_id": "NCT02747797", "title": "Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway Aberrations", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Cancer" ], "interventions": [ { "name": "Lucitanib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Teresa Helsten, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2017-04", "completion_date": "2022-04", "has_results": false, "last_update_posted_date": "2018-08-02", "last_synced_at": "2026-07-23T09:19:57.931Z", "location_count": 1, "location_summary": "La Jolla, California", "locations": [ { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02747797" }, { "nct_id": "NCT02924376", "title": "Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cholangiocarcinoma" ], "interventions": [ { "name": "Pemigatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 147, "start_date": "2017-01-16", "completion_date": "2022-02-01", "has_results": true, "last_update_posted_date": "2025-08-14", "last_synced_at": "2026-07-23T09:19:57.931Z", "location_count": 49, "location_summary": "Anchorage, Alaska • Phoenix, Arizona • Tempe, Arizona + 46 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02924376" }, { "nct_id": "NCT03656536", "title": "A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Unresectable Cholangiocarcinoma", "Metastatic Cholangiocarcinoma" ], "interventions": [ { "name": "Pemigatinib", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 167, "start_date": "2019-06-03", "completion_date": "2025-07-07", "has_results": false, "last_update_posted_date": "2025-08-24", "last_synced_at": "2026-07-23T09:19:57.931Z", "location_count": 36, "location_summary": "Phoenix, Arizona • Greenbrae, California • Orange, California + 29 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Greenbrae", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03656536" } ] }